Obesity as a risk factor for malignant melanoma and non-melanoma skin cancer

Reviews in Endocrine and Metabolic Disorders

Volumn 17, Issue 3, 2016, Pages 389-403

  Karimi, K ^a   Lindgren, T H ^a   Koch, C A ^b,c,d   Brodell, Robert T ^b,e  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Basal cell carcinoma; Inflammation; Insulin; Leptin; Melanoma; Non melanoma skin cancer; Obesity; Squamous cell carcinoma

Indexed keywords

ADIPONECTIN; DIURETIC AGENT; GLUCOCORTICOID; INSULIN; LEPTIN; MELANOCORTIN; NONSTEROID ANTIINFLAMMATORY AGENT; SOMATOMEDIN; VITAMIN D;

CANCER RISK; DIET; DISEASE ASSOCIATION; HUMAN; HYPOXEMIA; IMMUNE SYSTEM; INFLAMMATION; INSULIN RESISTANCE; MELANOMA; NON MELANOMA SKIN CANCER; NONHUMAN; OBESITY; OXIDATIVE STRESS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; COMPLICATION; IMMUNOLOGY; METABOLISM; SKIN NEOPLASMS;

HUMANS; MELANOMA; OBESITY; SKIN NEOPLASMS;

EID: 84994772079     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-016-9393-9     Document Type: Review

References (242)

1. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15(6):556–65. doi:10.1634/theoncologist.2009-0285.
2. Gallagher E, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev. 2015;95(3):727–48.
3. Albanes D, Winick M. Are cell number and cell proliferation risk factors for cancer? J Natl Cancer Inst. 1988;80(10):772–4.
4. Scrimshaw NS, SanGiovanni JP. Synergism of nutrition, infection, and immunity: an overview. Am J Clin Nutr. 1997;66(2):464S–77S.
5. Koch CA, Diamanti-Kandarakis E. Introduction to endocrine disrupting chemicals—is it time to act? Rev Endocr Metab Disord. 2015;16(4):269–70.
6. Kirkpatrick CS, White E, Lee JA. Case–control study of malignant melanoma in Washington State. II. Diet, alcohol, and obesity. Am J Epidemiol. 1994;139(9):869–80.
7. Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni Jr JF. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control. 2006;17(7):901–9. doi:10.1007/s10552-006-0023-9.
8. Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni Jr JF. Obesity and cancer risk among White and Black United States veterans. Cancer Causes Control. 2004;15(1):35–43. doi:10.1023/B:CACO.0000016573.79453.ba.
9. Dubin N, Moseson M, Pasternack BS. Epidemiology of malignant melanoma: pigmentary traits, ultraviolet radiation, and the identification of high-risk populations. Recent Results Cancer Res. 1986;102:56–75.
10. Gallus S, Naldi L, Martin L, Martinelli M, La Vecchia C. Oncology Study Group of the Italian Group for Epidemiologic Research in D. Anthropometric measures and risk of cutaneous malignant melanoma: a case–control study from Italy. Melanoma Res. 2006;16(1):83–7. doi:10.1097/01.cmr.0000194429.77643.76.
11. Dennis LK, Lowe JB, Lynch CF, Alavanja MC. Cutaneous melanoma and obesity in the Agricultural Health Study. Ann Epidemiol. 2008;18(3):214–21. doi:10.1016/j.annepidem.2007.09.003.
12. Tang JY, Henderson MT, Hernandez-Boussard T, Kubo J, Desai M, Sims ST, et al. Lower skin cancer risk in women with higher body mass index: the women’s health initiative observational study. Cancer Epidemiol Biomarkers Prev. 2013;22(12):2412–5. doi:10.1158/1055-9965.EPI-13-0647.
13. Pothiawala S, Qureshi AA, Li Y, Han J. Obesity and the incidence of skin cancer in US Caucasians. Cancer Causes Control: CCC. 2012;23(5):717–26. doi:10.1007/s10552-012-9941-x.
14. Sergentanis TN, Antoniadis AG, Gogas HJ, Antonopoulos CN, Adami HO, Ekbom A, et al. Obesity and risk of malignant melanoma: a meta-analysis of cohort and case–control studies. Eur J Cancer. 2013;49(3):642–57. doi:10.1016/j.ejca.2012.08.028.
15. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78. doi:10.1016/S0140-6736(08)60269-X.
16. Dobbins M, Decorby K, Choi BC. The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med. 2013;2013:680536. doi:10.5402/2013/680536.
17. Veierod MB, Thelle DS, Laake P. Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. Int J Cancer. 1997;71(4):600–4.
18. Olsen CM, Green AC, Zens MS, Stukel TA, Bataille V, Berwick M, et al. Anthropometric factors and risk of melanoma in women: a pooled analysis. Int J Cancer. 2008;122(5):1100–8. doi:10.1002/ijc.23214.
19. Praestegaard C, Kjaer SK, Christensen J, Tjonneland A, Halkjaer J, Jensen A. Obesity and risks for malignant melanoma and non-melanoma skin cancer: results from a large Danish prospective cohort study. J Invest Dermatol. 2015;135(3):901–4. doi:10.1038/jid.2014.438.
20. Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J. 2006;393(Pt 1):7–20. doi:10.1042/BJ20051578.
21. Courneya KS, Katzmarzyk PT, Bacon E. Physical activity and obesity in Canadian cancer survivors: population-based estimates from the 2005 Canadian Community Health Survey. Cancer. 2008;112(11):2475–82. doi:10.1002/cncr.23455.
22. Sahl WJ, Glore S, Garrison P, Oakleaf K, Johnson SD. Basal cell carcinoma and lifestyle characteristics. Int J Dermatol. 1995;34(6):398–402.
23. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288(14):1723–7.
24. Brandon EL, Gu JW, Cantwell L, He Z, Wallace G, Hall JE. Obesity promotes melanoma tumor growth: role of leptin. Cancer Biol Ther. 2009;8(19):1871–9.
25. Monteiro CA, Moura EC, Conde WL, Popkin BM. Socioeconomic status and obesity in adult populations of developing countries: a review. Bull World Health Organ. 2004;82(12):940–6.
26. Popkin BM, Gordon-Larsen P. The nutrition transition: worldwide obesity dynamics and their determinants. Int J Obes Relat Metab Disord. 2004;28 Suppl 3:S2–9. doi:10.1038/sj.ijo.0802804.
27. Li X, Liang L, Zhang M, Song F, Nan H, Wang LE, et al. Obesity-related genetic variants, human pigmentation, and risk of melanoma. Hum Genet. 2013;132(7):793–801. doi:10.1007/s00439-013-1293-4.
28. Frisancho AR, Wainwright R, Way A. Heritability and components of phenotypic expression in skin reflectance of Mestizos from the Peruvian lowlands. Am J Phys Anthropol. 1981;55(2):203–8. doi:10.1002/ajpa.1330550207.
29. Harrison GA, Owen JJ. Studies on the inheritance of human skin colour. Ann Hum Genet. 1964;28:27–37.
30. Turner JB, Kumar A, Koch CA. The effects of indoor and outdoor temperature on metabolic rate and adipose tissue—the Mississippi perspective on the obesity epidemic. Rev Endocr Metab Disord. 2016;17(1):61–71. doi:10.1007/s11154-016-9358-z.
31. Tai N, Wong FS, Wen L. The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity. Rev Endocr Metab Disord. 2015;16(1):55–65. doi:10.1007/s11154-015-9309-0.
32. Gerstenblith MR, Shi J, Landi MT. Genome-wide association studies of pigmentation and skin cancer: a review and meta-analysis. Pigment Cell Melanoma Res. 2010;23(5):587–606. doi:10.1111/j.1755-148X.2010.00730.x.
33. Nan H, Kraft P, Hunter DJ, Han J. Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer. 2009;125(4):909–17. doi:10.1002/ijc.24327.
34. McAllister EJ, Dhurandhar NV, Keith SW, Aronne LJ, Barger J, Baskin M, et al. Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr. 2009;49(10):868–913. doi:10.1080/10408390903372599.
35. Charriere G, Cousin B, Arnaud E, Andre M, Bacou F, Penicaud L, et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem. 2003;278(11):9850–5. doi:10.1074/jbc.M210811200.
36. Wang J, Ding N, Li Y, Cheng H, Wang D, Yang Q, et al. Insulin-like growth factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human melanoma cells. Oncotarget. 2015;6(24):20636–49.
37. Wang H, Ye J. Regulation of energy balance by inflammation: common theme in physiology and pathology. Rev Endocr Metab Disord. 2015;16(1):47–54.
38. Kloting N, Bluher M. Adipocyte dysfunction, inflammation and metabolic syndrome. Rev Endocr Metab Disord. 2014;15(4):277–87.
39. Ngo HT, Hetland RB, Nygaard UC, Steffensen IL. Genetic and diet-induced obesity increased intestinal tumorigenesis in the double mutant mouse model multiple intestinal neoplasia X obese via disturbed glucose regulation and inflammation. J Obes. 2015;2015:343479. doi:10.1155/2015/343479.
40. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175–84. doi:10.1172/JCI29881.
41. Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem. 2007;282(48):35279–92. doi:10.1074/jbc.M706762200.
42. Strissel KJ, Stancheva Z, Miyoshi H, Perfield 2nd JW, DeFuria J, Jick Z, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes. 2007;56(12):2910–8. doi:10.2337/db07-0767.
43. Zaldivar F, McMurray RG, Nemet D, Galassetti P, Mills PJ, Cooper DM. Body fat and circulating leukocytes in children. Int J Obes (Lond). 2006;30(6):906–11. doi:10.1038/sj.ijo.0803227.
44. Debnath M, Agrawal S, Agrawal A, Dubey GP. Metaflammatory responses during obesity: pathomechanism and treatment. Obes Res Clin Pract. 2015. doi:10.1016/j.orcp.2015.10.012.
45. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011;121(6):2111–7. doi:10.1172/JCI57132.
46. Shore SA. Environmental perturbations: obesity. Compr Physiol. 2011;1(1):263–82. doi:10.1002/cphy.c100017.
47. Atabek ME, Vatansev H, Erkul I. Oxidative stress in childhood obesity. J Pediatr Endocrinol Metab. 2004;17(8):1063–8.
48. Bakker SJ RGIJ, Teerlink T, Westerhoff HV, Gans RO, Heine RJ. Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure? Atherosclerosis. 2000;148(1):17–21.
49. Keaney Jr JF, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23(3):434–9. doi:10.1161/01.ATV.0000058402.34138.11.
50. Lee YS, Kim AY, Choi JW, Kim M, Yasue S, Son HJ, et al. Dysregulation of adipose glutathione peroxidase 3 in obesity contributes to local and systemic oxidative stress. Mol Endocrinol. 2008;22(9):2176–89. doi:10.1210/me.2008-0023.
51. Hernandez AR, Boada LD, Almeida-Gonzalez M, Mendoza Z, Ruiz-Suarez N, Valeron PF, et al. An estimation of the carcinogenic risk associated with the intake of multiple relevant carcinogens found in meat and charcuterie products. Sci Total Environ. 2015;514:33–41. doi:10.1016/j.scitotenv.2015.01.108.
52. Schut HA, Snyderwine EG. DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. Carcinogenesis. 1999;20(3):353–68.
53. Pei YF, Tian Q, Zhang L, Deng HW. Exploring the major sources and extent of heterogeneity in a genome-wide association meta-analysis. Ann Hum Genet. 2015. doi:10.1111/ahg.12143.
54. Holmes L, LaHurd A, Wasson E, McClarin L, Dabney K. Racial and ethnic heterogeneity in the association between total cholesterol and pediatric obesity. Int J Environ Res Public Health. 2015;13(1). doi:10.3390/ijerph13010019.
55. Perl A. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann N Y Acad Sci. 2015;1346(1):33–44. doi:10.1111/nyas.12756.
56. Cowen S, McLaughlin SL, Hobbs G, Coad J, Martin KH, Olfert IM, et al. High-fat, high-calorie diet enhances mammary carcinogenesis and local inflammation in MMTV-PyMT mouse model of breast cancer. Cancers (Basel). 2015;7(3):1125–42. doi:10.3390/cancers7030828.
57. Crujeiras AB, Cabia B, Carreira MC, Amil M, Cueva J, Andrade S, et al. Secreted factors derived from obese visceral adipose tissue regulate the expression of breast malignant transformation genes. Int J Obes (Lond). 2015. doi:10.1038/ijo.2015.208.
58. Gorlach A, Dimova EY, Petry A, Martinez-Ruiz A, Hernansanz-Agustin P, Rolo AP, et al. Reactive oxygen species, nutrition, hypoxia and diseases: problems solved? Redox Biol. 2015;6:372–85. doi:10.1016/j.redox.2015.08.016.
59. Hasan S, Suhail N, Bilal N, Ashraf GM, Zaidi SK, AlNohair S, et al. Chronic unpredictable stress deteriorates the chemopreventive efficacy of pomegranate through oxidative stress pathway. Tumour Biol. 2015. doi:10.1007/s13277-015-4469-9.
60. Manna P, Jain SK. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metab Syndr Relat Disord. 2015;13(10):423–44. doi:10.1089/met.2015.0095.
61. Hunsche C, Hernandez O, De la Fuente M. Impaired immune response in old mice suffering from obesity and premature immunosenescence in adulthood. J Gerontol A Biol Sci Med Sci. 2015. doi:10.1093/gerona/glv082.
62. Meyskens Jr FL, Farmer PJ, Anton-Culver H. Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk. Clin Cancer Res: Off J Am Assoc Cancer Res. 2004;10(8):2581–3.
63. Caslin HL, Franco RL, Crabb EB, Huang CJ, Bowen MK, Acevedo EO. The effect of obesity on inflammatory cytokine and leptin production following acute mental stress. Psychophysiology. 2015. doi:10.1111/psyp.12568.
64. Gogas H, Trakatelli M, Dessypris N, Terzidis A, Katsambas A, Chrousos GP, et al. Melanoma risk in association with serum leptin levels and lifestyle parameters: a case–control study. Ann Oncol. 2008;19(2):384–9. doi:10.1093/annonc/mdm464.
65. Dayakar A, Chandrasekaran S, Veronica J, Maurya RS. Leptin induces the phagocytosis and protective immune response in Leishmania donovani infected THP-1 cell line and human PBMCs. Exp Parasitol. 2015. doi:10.1016/j.exppara.2015.12.002.
66. Huang CJ, McAllister MJ, Slusher AL, Webb HE, Mock JT, Acevedo EO. Obesity-related oxidative stress: the impact of physical activity and diet manipulation. Sports Med Open. 2015;1(1):32. doi:10.1186/s40798-015-0031-y.
67. Mizutani H, Fukushima S, Masuguchi S, Yamashita J, Miyashita A, Nakahara S, et al. Serum levels of leptin receptor in patients with malignant melanoma as a new tumor marker. Exp Dermatol. 2013;22(11):748–9. doi:10.1111/exd.12238.
68. Chirumbolo S. The role of vitamin D towards immune tolerance in white adipose tissue (WAT). Endocr Metab Immune Disord Drug Targets. 2015;15(4):277–87.
69. Yao Y, Zhu L, He L, Duan Y, Liang W, Nie Z, et al. A meta-analysis of the relationship between vitamin D deficiency and obesity. Int J Clin Exp Med. 2015;8(9):14977–84.
70. Lagunova Z, Porojnicu AC, Grant WB, Bruland O, Moan JE. Obesity and increased risk of cancer: does decrease of serum 25-hydroxyvitamin D level with increasing body mass index explain some of the association? Mol Nutr Food Res. 2010;54(8):1127–33. doi:10.1002/mnfr.200900512.
71. Kremer R, Campbell PP, Reinhardt T, Gilsanz V. Vitamin D status and its relationship to body fat, final height, and peak bone mass in young women. J Clin Endocrinol Metab. 2009;94(1):67–73. doi:10.1210/jc.2008-1575.
72. Bikle DD. Vitamin D, and the skin: physiology and pathophysiology. Rev Endocr Metab Disord. 2012;13(1):3–19.
73. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004;79(3):362–71.
74. Lackey DE, Olefsky JM. Regulation of metabolism by the innate immune system. Nat Rev Endocrinol. 2016;12(1):15–28. doi:10.1038/nrendo.2015.189.
75. Zeyda M, Stulnig TM. Adipose tissue macrophages. Immunol Lett. 2007;112(2):61–7. doi:10.1016/j.imlet.2007.07.003.
76. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546. doi:10.1155/2013/291546.
77. Saraiya A, Al-Shoha A, Brodell RT. Hyperinsulinemia associated with acanthosis nigricans, finger pebbles, acrochordons, and the sign of Leser-Trelat. Endocr Pract. 2013;19(3):522–5. doi:10.4158/EP12192.RA.
78. East HE, Subauste JS, Gandhi A, Koch CA. About secondary causes of diabetes mellitus. J Miss State Med Assoc. 2012;53(11):380–3.
79. Cheng S, Gomez K, Serri O, Chik C, Ezzat S. The role of diabetes in acromegaly associated neoplasia. PLoS One. 2015;10(5), e0127276. doi:10.1371/journal.pone.0127276.
80. Su Y, Carey LC, Rose JC, Pulgar VM. Leptin alters adrenal responsiveness by decreasing expression of ACTH-R, StAR, and P450c21 in hypoxemic fetal sheep. Reprod Sci. 2012;19(10):1075–84. doi:10.1177/1933719112442246.
81. Ellerhorst JA, Diwan AH, Dang SM, Uffort DG, Johnson MK, Cooke CP, et al. Promotion of melanoma growth by the metabolic hormone leptin. Oncol Rep. 2010;23(4):901–7.
82. de Vries E, Coebergh JW. Cutaneous malignant melanoma in Europe. Eur J Cancer. 2004;40(16):2355–66. doi:10.1016/j.ejca.2004.06.003.
83. Lasithiotakis KG, Leiter U, Gorkievicz R, Eigentler T, Breuninger H, Metzler G, et al. The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer. 2006;107(6):1331–9. doi:10.1002/cncr.22126.
84. Mansson-Brahme E, Johansson H, Larsson O, Rutqvist LE, Ringborg U. Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976–1994. Acta Oncol. 2002;41(2):138–46.
85. Stang A, Pukkala E, Sankila R, Soderman B, Hakulinen T. Time trend analysis of the skin melanoma incidence of Finland from 1953 through 2003 including 16,414 cases. Int J Cancer. 2006;119(2):380–4. doi:10.1002/ijc.21836.
86. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129(7):1666–74. doi:10.1038/jid.2008.423.
87. Ortiz CA, Goodwin JS, Freeman JL. The effect of socioeconomic factors on incidence, stage at diagnosis and survival of cutaneous melanoma. Med Sci Monit. 2005;11(5):RA163–72.
88. Pollitt RA, Clarke CA, Shema SJ, Swetter SM. California Medicaid enrollment and melanoma stage at diagnosis: a population-based study. Am J Prev Med. 2008;35(1):7–13. doi:10.1016/j.amepre.2008.03.026.
89. Roetzheim RG, Pal N, Tennant C, Voti L, Ayanian JZ, Schwabe A, et al. Effects of health insurance and race on early detection of cancer. J Natl Cancer Inst. 1999;91(16):1409–15.
90. Diffey B. Climate change, ozone depletion and the impact on ultraviolet exposure of human skin. Phys Med Biol. 2004;49(1):R1–11.
91. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ. 2005;331(7515):481. doi:10.1136/bmj.38516.649537.E0.
92. Hall HI, Jamison P, Fulton JP, Clutter G, Roffers S, Parrish P. Reporting cutaneous melanoma to cancer registries in the United States. J Am Acad Dermatol. 2003;49(4):624–30.
93. Swerlick RA, Chen S. The melanoma epidemic. Is increased surveillance the solution or the problem? Arch Dermatol. 1996;132(8):881–4.
94. Swerlick RA, Chen S. The melanoma epidemic: more apparent than real? Mayo Clin Proc. 1997;72(6):559–64. doi:10.1016/S0025-6196(11)63306-5.
95. Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: a meta-analysis of nevi and melanoma. Cancer Prev Res (Phila). 2010;3(2):233–45. doi:10.1158/1940-6207.CAPR-09-0108.
96. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41(14):2040–59. doi:10.1016/j.ejca.2005.03.034.
97. Wheless L, Black J, Alberg AJ. Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1686–95. doi:10.1158/1055-9965.EPI-10-0243.
98. Chen ST, Geller AC, Tsao H. Update on the epidemiology of melanoma. Curr Dermatol Rep. 2013;2(1):24–34. doi:10.1007/s13671-012-0035-5.
99. Pappo AS, Armstrong GT, Liu W, Srivastava DK, McDonald A, Leisenring WM, et al. Melanoma as a subsequent neoplasm in adult survivors of childhood cancer: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2013;60(3):461–6. doi:10.1002/pbc.24266.
100. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41(1):45–60. doi:10.1016/j.ejca.2004.10.016.
101. Rigel DS, Rigel EG, Rigel AC. Effects of altitude and latitude on ambient UVB radiation. J Am Acad Dermatol. 1999;40(1):114–6.
102. Bulliard JL. Site-specific risk of cutaneous malignant melanoma and pattern of sun exposure in New Zealand. Int J Cancer. 2000;85(5):627–32.
103. Parisi AV, Kimlin MG, Lester R, Turnbull D. Lower body anatomical distribution of solar ultraviolet radiation on the human form in standing and sitting postures. J Photochem Photobiol B. 2003;69(1):1–6.
104. Reed KB, Brewer JD, Lohse CM, Bringe KE, Pruitt CN, Gibson LE. Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County. Minnesota Mayo Clin Proc. 2012;87(4):328–34. doi:10.1016/j.mayocp.2012.01.010.
105. Stryker WS, Stampfer MJ, Stein EA, Kaplan L, Louis TA, Sober A, et al. Diet, plasma levels of beta-carotene and alpha-tocopherol, and risk of malignant melanoma. Am J Epidemiol. 1990;131(4):597–611.
106. Bain C, Green A, Siskind V, Alexander J, Harvey P. Diet and melanoma. An exploratory case–control study. Ann Epidemiol. 1993;3(3):235–8.
107. Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Guerry D, et al. Diet and melanoma in a case–control study. Cancer Epidemiol Biomarkers Prev. 2004;13(6):1042–51.
108. Meyskens Jr FL, Farmer PJ, Anton-Culver H. Diet and melanoma in a case–control study. Cancer Epidemiol Biomarkers Prev. 2005;14(1):293.
109. Le Marchand L, Saltzman BS, Hankin JH, Wilkens LR, Franke AA, Morris SJ, et al. Sun exposure, diet, and melanoma in Hawaii Caucasians. Am J Epidemiol. 2006;164(3):232–45. doi:10.1093/aje/kwj115.
110. Nicolopoulou-Stamati P, Hens L, Sasco AJ. Cosmetics as endocrine disruptors: are they a health risk? Rev Endocr Metab Disord. 2015;16(4):373–83.
111. Holland KT, Bojar RA. Cosmetics: what is their influence on the skin microflora? Am J Clin Dermatol. 2002;3(7):445–9.
112. Karpuzoglu E, Holladay SD, Gogal Jr RM. Parabens: potential impact of low-affinity estrogen receptor binding chemicals on human health. J Toxicol Environ Health B Crit Rev. 2013;16(5):321–35. doi:10.1080/10937404.2013.809252.
113. Gandini S, Iodice S, Koomen E, Di Pietro A, Sera F, Caini S. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer. 2011;47(17):2607–17. doi:10.1016/j.ejca.2011.04.023.
114. Ward EM, Burnett CA, Ruder A, Davis-King K. Industries and cancer. Cancer Causes Control. 1997;8(3):356–70.
115. Sinks T, Steele G, Smith AB, Watkins K, Shults RA. Mortality among workers exposed to polychlorinated biphenyls. Am J Epidemiol. 1992;136(4):389–98.
116. Loomis D, Browning SR, Schenck AP, Gregory E, Savitz DA. Cancer mortality among electric utility workers exposed to polychlorinated biphenyls. Occup Environ Med. 1997;54(10):720–8.
117. Robinson CF, Petersen M, Palu S. Mortality patterns among electrical workers employed in the U.S. construction industry, 1982–1987. Am J Ind Med. 1999;36(6):630–7.
118. Nelemans PJ, Scholte R, Groenendal H, Kiemeney LA, Rampen FH, Ruiter DJ, et al. Melanoma and occupation: results of a case–control study in The Netherlands. Br J Ind Med. 1993;50(7):642–6.
119. Gantz I, Fong TM. The melanocortin system. Am J Physiol Endocrinol Metab. 2003;284(3):E468–74. doi:10.1152/ajpendo.00434.2002.
120. Danforth CH. Hereditary adiposity in mice. Obes Res. 1996;4(1):96–100.
121. Dickies MM. A new viable yellow mutation in the house mouse. J Hered. 1962;53:84–6.
122. Heston WE, Vlahakis G. Influence of the Ay gene on mammary-gland tumors, hepatomas, and normal growth in mice. J Natl Cancer Inst. 1961;26:969–83.
123. Heston WE, Vlahakis G. C3H-Avy—a high hepatoma and high mammary tumor strain of mice. J Natl Cancer Inst. 1968;40(6):1161–6.
124. Yen TT, Gill AM, Frigeri LG, Barsh GS, Wolff GL. Obesity, diabetes, and neoplasia in yellow A(vy)/- mice: ectopic expression of the agouti gene. FASEB J. 1994;8(8):479–88.
125. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19(2):155–7. doi:10.1038/509.
126. Millington GW. Proopiomelanocortin (POMC): the cutaneous roles of its melanocortin products and receptors. Clin Exp Dermatol. 2006;31(3):407–12. doi:10.1111/j.1365-2230.2006.02128.x.
127. Ramachandrappa S, Farooqi IS. Genetic approaches to understanding human obesity. J Clin Invest. 2011;121(6):2080–6. doi:10.1172/JCI46044.
128. D’Orazio JA, Nobuhisa T, Cui R, Arya M, Spry M, Wakamatsu K, et al. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature. 2006;443(7109):340–4. doi:10.1038/nature05098.
129. Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell. 2007;128(5):853–64. doi:10.1016/j.cell.2006.12.045.
130. Sato HNY, Chrousos GP, Ichihashi M, Funasak Y. The expression of corticotropin-releasing hormone in melanoma. Pigment Cell Res. 2002;15(2):98–103.
131. Millington GW. The role of proopiomelanocortin (POMC) neurones in feeding behaviour. Nutr Metab (Lond). 2007;4:18. doi:10.1186/1743-7075-4-18.
132. Sharma SD, Katiyar SK. Leptin deficiency-induced obesity exacerbates ultraviolet B radiation-induced cyclooxygenase-2 expression and cell survival signals in ultraviolet B-irradiated mouse skin. Toxicol Appl Pharmacol. 2010;244(3):328–35. doi:10.1016/j.taap.2010.01.010.
133. Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–96. doi:10.1016/j.cell.2015.05.044.
134. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol. 2006;207(1):12–22. doi:10.1002/jcp.20472.
135. Tessitore L, Vizio B, Jenkins O, De Stefano I, Ritossa C, Argiles JM, et al. Leptin expression in colorectal and breast cancer patients. Int J Mol Med. 2000;5(4):421–6.
136. Petridou E, Belechri M, Dessypris N, Koukoulomatis P, Diakomanolis E, Spanos E, et al. Leptin and body mass index in relation to endometrial cancer risk. Ann Nutr Metab. 2002;46(3–4):147–51.
137. Stattin P, Palmqvist R, Soderberg S, Biessy C, Ardnor B, Hallmans G, et al. Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncol Rep. 2003;10(6):2015–21.
138. Arnardottir ES, Maislin G, Jackson N, Schwab RJ, Benediktsdottir B, Teff K, et al. The role of obesity, different fat compartments and sleep apnea severity in circulating leptin levels: the Icelandic Sleep Apnea Cohort study. Int J Obes (Lond). 2013;37(6):835–42. doi:10.1038/ijo.2012.138.
139. Leroy P, Dessolin S, Villageois P, Moon BC, Friedman JM, Ailhaud G, et al. Expression of ob gene in adipose cells. Regulation by insulin. J Biol Chem. 1996;271(5):2365–8.
140. Zhang HH, Kumar S, Barnett AH, Eggo MC. Tumour necrosis factor-alpha exerts dual effects on human adipose leptin synthesis and release. Mol Cell Endocrinol. 2000;159(1–2):79–88.
141. Dagogo-Jack S, Selke G, Melson AK, Newcomer JW. Robust leptin secretory responses to dexamethasone in obese subjects. J Clin Endocrinol Metab. 1997;82(10):3230–3. doi:10.1210/jcem.82.10.4154.
142. Machinal-Quelin F, Dieudonne MN, Pecquery R, Leneveu MC, Giudicelli Y. Direct in vitro effects of androgens and estrogens on ob gene expression and leptin secretion in human adipose tissue. Endocrine. 2002;18(2):179–84. doi:10.1385/ENDO:18:2:179.
143. Fain JN, Leffler CW, Bahouth SW. Eicosanoids as endogenous regulators of leptin release and lipolysis by mouse adipose tissue in primary culture. J Lipid Res. 2000;41(10):1689–94.
144. Oba J, Wei W, Gershenwald JE, Johnson MM, Wyatt CM, Ellerhorst JA, et al. Elevated serum leptin levels are associated with an increased risk of sentinel lymph node metastasis in cutaneous melanoma. Medicine (Baltimore). 2016;95(11), e3073. doi:10.1097/MD.0000000000003073.
145. Jung JI, Cho HJ, Jung YJ, Kwon SH, Her S, Choi SS, et al. High-fat diet-induced obesity increases lymphangiogenesis and lymph node metastasis in the B16F10 melanoma allograft model: roles of adipocytes and M2-macrophages. Int J Cancer. 2015;136(2):258–70. doi:10.1002/ijc.28983.
146. McMurphy T, Xiao R, Magee D, Slater A, Zabeau L, Tavernier J, et al. The anti-tumor activity of a neutralizing nanobody targeting leptin receptor in a mouse model of melanoma. PLoS ONE. 2014;9(2), e89895. doi:10.1371/journal.pone.0089895.
147. Emilsson V, Liu YL, Cawthorne MA, Morton NM, Davenport M. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes. 1997;46(2):313–6.
148. Kulkarni RN, Wang ZL, Wang RM, Hurley JD, Smith DM, Ghatei MA, et al. Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets, and in vivo, in mice. J Clin Invest. 1997;100(11):2729–36. doi:10.1172/JCI119818.
149. Morris DL, Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab. 2009;297(6):E1247–59. doi:10.1152/ajpendo.00274.2009.
150. Wang MY, Lee Y, Unger RH. Novel form of lipolysis induced by leptin. J Biol Chem. 1999;274(25):17541–4.
151. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995;269(5223):546–9.
152. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269(5223):543–6.
153. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;269(5223):540–3.
154. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature. 1995;377(6549):530–2. doi:10.1038/377530a0.
155. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet. 1996;348(9021):159–61.
156. El-Haschimi K, Pierroz DD, Hileman SM, Bjorbaek C, Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest. 2000;105(12):1827–32. doi:10.1172/JCI9842.
157. Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte Jr D. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med. 1996;2(5):589–93.
158. Belouzard S, Delcroix D, Rouille Y. Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway. J Biol Chem. 2004;279(27):28499–508. doi:10.1074/jbc.M400508200.
159. Diano S, Kalra SP, Horvath TL. Leptin receptor immunoreactivity is associated with the Golgi apparatus of hypothalamic neurons and glial cells. J Neuroendocrinol. 1998;10(9):647–50.
160. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387(6636):903–8. doi:10.1038/43185.
161. Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet. 1998;18(3):213–5. doi:10.1038/ng0398-213.
162. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–32. doi:10.1038/372425a0.
163. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol. 2008;52(15):1201–10. doi:10.1016/j.jacc.2008.05.060.
164. Mantzoros CS, Liolios AD, Tritos NA, Kaklamani VG, Doulgerakis DE, Griveas I, et al. Circulating insulin concentrations, smoking, and alcohol intake are important independent predictors of leptin in young healthy men. Obes Res. 1998;6(3):179–86.
165. Traish AM, Zitzmann M. The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. Rev Endocr Metab Disord. 2015;16(3):249–68. doi:10.1007/s11154-015-9323-2.
166. Ullah MI, Washington T, Kazi M, Tamanna S, Koch CA. Testosterone deficiency as a risk factor for cardiovascular disease. Horm Metab Res. 2011;43(03):153–64.
167. Coppari R, Bjorbaek C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov. 2012;11(9):692–708. doi:10.1038/nrd3757.
168. Stanley BG, Leibowitz SF. Neuropeptide Y injected in the paraventricular hypothalamus: a powerful stimulant of feeding behavior. Proc Natl Acad Sci U S A. 1985;82(11):3940–3.
169. Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009;9(1):35–51. doi:10.1016/j.cmet.2008.12.004.
170. Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell. 2008;135(1):61–73. doi:10.1016/j.cell.2008.07.043.
171. Ogimoto K, Harris Jr MK, Wisse BE. MyD88 is a key mediator of anorexia, but not weight loss, induced by lipopolysaccharide and interleukin-1 beta. Endocrinology. 2006;147(9):4445–53. doi:10.1210/en.2006-0465.
172. Ozcan U, Ozcan L, Yilmaz E, Duvel K, Sahin M, Manning BD, et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell. 2008;29(5):541–51. doi:10.1016/j.molcel.2007.12.023.
173. Hosoi T, Sasaki M, Miyahara T, Hashimoto C, Matsuo S, Yoshii M, et al. Endoplasmic reticulum stress induces leptin resistance. Mol Pharmacol. 2008;74(6):1610–9. doi:10.1124/mol.108.050070.
174. Lam QL, Lu L. Role of leptin in immunity. Cell Mol Immunol. 2007;4(1):1–13.
175. Chen K, Li F, Li J, Cai H, Strom S, Bisello A, et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med. 2006;12(4):425–32. doi:10.1038/nm1372.
176. Amjadi F, Javanmard SH, Zarkesh-Esfahani H, Khazaei M, Narimani M. Leptin promotes melanoma tumor growth in mice related to increasing circulating endothelial progenitor cells numbers and plasma NO production. J Exp Clin Cancer Res. 2011;30:21. doi:10.1186/1756-9966-30-21.
177. Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol. 2007;170(1):1–15. doi:10.2353/ajpath.2007.060302.
178. Gonzalez RR, Cherfils S, Escobar M, Yoo JH, Carino C, Styer AK, et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem. 2006;281(36):26320–8. doi:10.1074/jbc.M601991200.
179. Ribatti D, Nico B, Belloni AS, Vacca A, Roncali L, Nussdorfer GG. Angiogenic activity of leptin in the chick embryo chorioallantoic membrane is in part mediated by endogenous fibroblast growth factor-2. Int J Mol Med. 2001;8(3):265–8.
180. Lago R, Gomez R, Lago F, Gomez-Reino J, Gualillo O. Leptin beyond body weight regulation—current concepts concerning its role in immune function and inflammation. Cell Immunol. 2008;252(1–2):139–45. doi:10.1016/j.cellimm.2007.09.004.
181. Artwohl M, Roden M, Holzenbein T, Freudenthaler A, Waldhausl W, Baumgartner-Parzer SM. Modulation by leptin of proliferation and apoptosis in vascular endothelial cells. Int J Obes Relat Metab Disord. 2002;26(4):577–80.
182. Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000;62:413–37. doi:10.1146/annurev.physiol.62.1.413.
183. Grosfeld A, Andre J, Hauguel-De Mouzon S, Berra E, Pouyssegur J, Guerre-Millo M. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J Biol Chem. 2002;277(45):42953–7. doi:10.1074/jbc.M206775200.
184. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004;101(8):2476–81.
185. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000;96(5):1723–32.
186. Kang JH, Lee YY, Yu BY, Yang BS, Cho KH, Yoon DK, et al. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res. 2005;28(11):1263–9.
187. Ogunwobi OO, Beales IL. Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept. 2006;134(2–3):105–13. doi:10.1016/j.regpep.2006.02.001.
188. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun. 2006;340(4):1158–66. doi:10.1016/j.bbrc.2005.12.103.
189. Arditi JD, Venihaki M, Karalis KP, Chrousos GP. Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res. 2007;39(1):9–13. doi:10.1055/s-2007-956518.
190. Mantzoros CS, Trakatelli M, Gogas H, Dessypris N, Stratigos A, Chrousos GP, et al. Circulating adiponectin levels in relation to melanoma: a case–control study. Eur J Cancer. 2007;43(9):1430–6. doi:10.1016/j.ejca.2007.03.026.
191. Gallagher EJ, Fierz Y, Ferguson RD, LeRoith D. The pathway from diabetes and obesity to cancer, on the route to targeted therapy. Endocr Pract. 2010;16(5):864–73. doi:10.4158/EP10098.RA.
192. Moore T, Carbajal S, Beltran L, Perkins SN, Yakar S, Leroith D, et al. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I levels. Cancer Res. 2008;68(10):2680–8.
193. Sadagurski MYS, Weingarten G, Holzenberger M, Rhodes CJ, Breitkreutz D, Leroith D, et al. Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation. Mol Cell Biol. 2006;26(7):2675–87.
194. Chi M, Ye Y, Zhang XD, Chen J. Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway. Drug Des Devel Ther. 2014;8:255–62. doi:10.2147/DDDT.S53568.
195. Kucera R, Treskova I, Vrzalova J, Svobodova S, Topolcan O, Fuchsova R, et al. Evaluation of IGF1 serum levels in malignant melanoma and healthy subjects. Anticancer Res. 2014;34(9):5217–20.
196. Naspi A, Panasiti V, Abbate F, Roberti V, Devirgiliis V, Curzio M, et al. Insulin-like-growth-factor-binding-protein-3 (IGFBP-3) contrasts melanoma progression in vitro and in vivo. PLoS One. 2014;9(6), e98641. doi:10.1371/journal.pone.0098641.
197. Jones SA, Morand EF. Glucocorticoids in 2015: new answers to old problems. Nat Rev Rheumatol. 2015. doi:10.1038/nrrheum.2015.176.
198. Bhakoo HS, Milholland RJ, Lopez R, Karakousis C, Rosen F. High incidence and characterization of glucocorticoid receptors in human malignant melanoma. J Natl Cancer Inst. 1981;66(1):21–5.
199. Dobos J, Kenessey I, Timar J, Ladanyi A. Glucocorticoid receptor expression and antiproliferative effect of dexamethasone on human melanoma cells. Pathol Oncol Res. 2011;17(3):729–34. doi:10.1007/s12253-011-9377-8.
200. Spencer SJ, Tilbrook A. The glucocorticoid contribution to obesity. Stress. 2011;14(3):233–46. doi:10.3109/10253890.2010.534831.
201. Livingstone DE, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ, et al. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology. 2000;141(2):560–3. doi:10.1210/endo.141.2.7297.
202. Shoag J, Haq R, Zhang M, Liu L, Rowe GC, Jiang A, et al. PGC-1 coactivators regulate MITF and the tanning response. Mol Cell. 2013;49(1):145–57. doi:10.1016/j.molcel.2012.10.027.
203. Price RA, Li WD, Zhao H. FTO gene SNPs associated with extreme obesity in cases, controls and extremely discordant sister pairs. BMC Med Genet. 2008;9:4. doi:10.1186/1471-2350-9-4.
204. Ghosh S, Murinova L, Trnovec T, Loffredo CA, Washington K, Mitra PS, et al. Biomarkers linking PCB exposure and obesity. Curr Pharm Biotechnol. 2014;15(11):1058–68.
205. De Coster S, van Larebeke N. Endocrine-disrupting chemicals: associated disorders and mechanisms of action. J Environ Public Health. 2012;2012:713696. doi:10.1155/2012/713696.
206. Koch CA. EDITORIAL: “The Koch’s” view on the sense of taste in endocrinology. Rev Endocr Metab Disord. 2016;17(2):143–7. doi:10.1007/s11154-016-9383-y.
207. Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277–304. doi:10.2165/11599410-000000000-00000.
208. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20. doi:10.1001/jama.2013.284427.
209. McDonald E, Freedman DM, Alexander BH, Doody MM, Tucker MA, Linet MS, et al. Prescription diuretic use and risk of basal cell carcinoma in the nationwide U.S. radiologic technologists cohort. Cancer Epidemiol Biomarkers Prev. 2014;23(8):1539–45. doi:10.1158/1055-9965.EPI-14-0251.
210. Robinson SN, Zens MS, Perry AE, Spencer SK, Duell EJ, Karagas MR. Photosensitizing agents and the risk of non-melanoma skin cancer: a population-based case–control study. J Invest Dermatol. 2013;133(8):1950–5. doi:10.1038/jid.2013.33.
211. Kaae J, Boyd HA, Hansen AV, Wulf HC, Wohlfahrt J, Melbye M. Photosensitizing medication use and risk of skin cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(11):2942–9. doi:10.1158/1055-9965.EPI-10-0652.
212. Ruiter R, Visser LE, Eijgelsheim M, Rodenburg EM, Hofman A, Coebergh JW, et al. High-ceiling diuretics are associated with an increased risk of basal cell carcinoma in a population-based follow-up study. Eur J Cancer. 2010;46(13):2467–72. doi:10.1016/j.ejca.2010.04.024.
213. Glatz M, Hofbauer GF. Phototoxic and photoallergic cutaneous drug reactions. Chem Immunol Allergy. 2012;97:167–79. doi:10.1159/000335630.
214. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf. 2002;25(5):345–72.
215. Stern RS. Photocarcinogenicity of drugs. Toxicol Lett. 1998;102–103:389–92.
216. Stern RS, Bigby M. An expanded profile of cutaneous reactions to nonsteroidal anti-inflammatory drugs. Reports to a specialty-based system for spontaneous reporting of adverse reactions to drugs. JAMA. 1984;252(11):1433–7.
217. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Risk of skin reactions when using ibuprofen-based medicines. Expert Opin Drug Saf. 2005;4(5):837–48. doi:10.1517/14740338.4.5.837.
218. Finch LE, Tomiyama AJ. Comfort eating, psychological stress, and depressive symptoms in young adult women. Appetite. 2015;95:239–44. doi:10.1016/j.appet.2015.07.017.
219. Bliss SA, Warnock JK. Psychiatric medications: adverse cutaneous drug reactions. Clin Dermatol. 2013;31(1):101–9. doi:10.1016/j.clindermatol.2011.11.014.
220. Borras L, Huguelet P. A case report of photosensitivity to amisulpride. Prim Care Companion J Clin Psychiatry. 2007;9(2):153.
221. Warnock JK, Morris DW. Adverse cutaneous reactions to antipsychotics. Am J Clin Dermatol. 2002;3(9):629–36.
222. Mennella JA, Bobowski NK, Reed DR. The development of sweet taste: from biology to hedonics. Rev Endocr Metab Disord. 2016;17(2):171–8. doi:10.1007/s11154-016-9360-5.
223. Iwasaki JK, Srivastava D, Moy RL, Lin HJ, Kouba DJ. The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics. J Am Acad Dermatol. 2012;66(5):e167–78. doi:10.1016/j.jaad.2010.06.054.
224. Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet. 2016;48(4):398–406. doi:10.1038/ng.3525.
225. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283–7. doi:10.1001/archdermatol.2010.19.
226. Makrantonaki EZC. Molecular mechanisms of skin aging: state of the art. Acad Sci. 2007;1119:40–50.
227. Yan W, Wistuba II, Emmert-Buck MR, Erickson HS. Squamous cell carcinoma—similarities and differences among anatomical sites. Am J Cancer Res. 2011;1(3):275–300.
228. Ibiebele TI, van der Pols JC, Hughes MC, Marks GC, Williams GM, Green AC. Dietary pattern in association with squamous cell carcinoma of the skin: a prospective study. Am J Clin Nutr. 2007;85(5):1401–8.
229. Inoue T, Toda S, Narisawa Y, Sugihara H. Subcutaneous adipocytes promote the differentiation of squamous cell carcinoma cell line (DJM-1) in collagen gel matrix culture. J Invest Dermatol. 2001;117(2):244–50. doi:10.1046/j.0022-202x.2001.01431.x.
230. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353(21):2262–9. doi:10.1056/NEJMra044151.
231. Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88(2):167–79.
232. Espinosa P, Pfeiffer RM, Garcia-Casado Z, Requena C, Landi MT, Kumar R, et al. Risk factors for keratinocyte skin cancer in patients diagnosed with melanoma, a large retrospective study. Eur J Cancer. 2015;53:115–24. doi:10.1016/j.ejca.2015.10.058.
233. Reinau D, Surber C, Jick SS, Meier CR. Epidemiology of basal cell carcinoma in the United Kingdom: incidence, lifestyle factors, and comorbidities. Br J Cancer. 2014;111(1):203–6. doi:10.1038/bjc.2014.265.
234. Baxter JM, Patel AN, Varma S. Facial basal cell carcinoma. BMJ. 2012;345, e5342. doi:10.1136/bmj.e5342.
235. Cheng P, Weng SD, Chiang CH, Lai FJ. Relationship between arsenic-containing drinking water and skin cancers in the arseniasis endemic areas in Taiwan. J Dermatol. 2016;43(2):181–6.
236. Poschl G, Seitz HK. Alcohol and cancer. Alcohol Alcohol. 2004;39(3):155–65.
237. Saladi RN, Nektalova T, Fox JL. Induction of skin carcinogenicity by alcohol and ultraviolet light. Clin Exp Dermatol. 2010;35(1):7–11. doi:10.1111/j.1365-2230.2009.03465.x.
238. Song F, Qureshi AA, Gao X, Li T, Han J. Smoking and risk of skin cancer: a prospective analysis and a meta-analysis. Int J Epidemiol. 2012;41(6):1694–705. doi:10.1093/ije/dys146.
239. Leonardi-Bee J, Ellison T, Bath-Hextall F. Smoking and the risk of nonmelanoma skin cancer: systematic review and meta-analysis. Arch Dermatol. 2012;148(8):939–46. doi:10.1001/archdermatol.2012.1374.
240. Hughes MC, Olsen CM, Williams GM, Green AC. A prospective study of cigarette smoking and basal cell carcinoma. Arch Dermatol Res. 2014;306(9):851–6. doi:10.1007/s00403-014-1503-5.
241. Henderson MT, Kubo JT, Desai M, David SP, Tindle H, Sinha AA, et al. Smoking behavior and association of melanoma and nonmelanoma skin cancer in the Women’s Health Initiative. J Am Acad Dermatol. 2015;72(1):190–1. doi:10.1016/j.jaad.2014.09.024. e3.
242. Trost SG, Owen N, Bauman AE, Sallis JF, Brown W. Correlates of adults’ participation in physical activity: review and update. Med Sci Sports Exerc. 2002;34(12):1996–2001. doi:10.1249/01.MSS.0000038974.76900.92.